MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

Search

Sanofi

Geschlossen

48.13 1.43

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

47.49

Max

48.66

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.1B

2.8B

Verkäufe

2.4B

13B

KGV

Branchendurchschnitt

15.698

88.032

Gewinnspanne

21.276

Angestellte

82,878

EBITDA

2.3B

4.2B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+70.68% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-6B

117B

Vorheriger Eröffnungskurs

46.7

Vorheriger Schlusskurs

48.13

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Sanofi Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Dez. 2025, 11:40 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal -- Update

24. Dez. 2025, 11:17 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Dynavax Shares Leap Premarket on Takeover by Sanofi

24. Dez. 2025, 06:55 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

15. Dez. 2025, 10:11 UTC

Wichtige Markttreiber

Sanofi Shares Fall After Multiple Sclerosis Drug Gets Hit by Double Setback

24. Okt. 2025, 08:29 UTC

Ergebnisse

Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue -- Update

24. Okt. 2025, 07:00 UTC

Ergebnisse

Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance

31. Dez. 2025, 08:49 UTC

Market Talk

Sanofi's Pipeline Weakness Likely to Hamper Growth -- Market Talk

24. Dez. 2025, 17:08 UTC

Akquisitionen, Fusionen, Übernahmen

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24. Dez. 2025, 12:59 UTC

Akquisitionen, Fusionen, Übernahmen

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24. Dez. 2025, 06:41 UTC

Akquisitionen, Fusionen, Übernahmen

Correct: Sanofi: Deal Expected to Have No Impact on 2025 Guidance

24. Dez. 2025, 06:19 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Acquisition to Close in 1Q of 2026

24. Dez. 2025, 06:19 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Deal Expected to Have on Impact on 2025 Guidance

24. Dez. 2025, 06:19 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Offering $15.50 a Share in Cash for Dynavax

24. Dez. 2025, 06:18 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Start Cash Tender Offer at Equity Value of $2.2B

24. Dez. 2025, 06:18 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Deal Adds Marketed Adult Hepatitis B Vaccine, Phase 1/2 Shingles Candidate

24. Dez. 2025, 06:17 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Vaccine Company Dynavax Technologies

24. Dez. 2025, 06:16 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Dynavax

24. Dez. 2025, 06:15 UTC

Akquisitionen, Fusionen, Übernahmen

Press Release: Sanofi To Acquire Dynavax, Adding A Marketed Adult Hepatitis B Vaccine And Phase 1/2 Shingles Candidate To The Pipeline >SAN.FR

15. Dez. 2025, 15:03 UTC

Market Talk

Sanofi Multiple Sclerosis Trial Failure Leaves FDA Approval in Doubt -- Market Talk

15. Dez. 2025, 13:59 UTC

Heiße Aktien

Stocks to Watch Monday: iRobot, Tilray, EchoStar, Juventus -- WSJ

15. Dez. 2025, 11:18 UTC

Market Talk

Sanofi's Multiple Sclerosis Drug Fails Late-Stage Trial; Latest Pipeline Setback -- Market Talk

15. Dez. 2025, 09:53 UTC

Heiße Aktien

Stocks to Watch Monday: iRobot, EchoStar, Rocket Lab, Alibaba -- WSJ

4. Dez. 2025, 10:02 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Completes Acquisition of Vicebio

4. Dez. 2025, 10:01 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Buys Vicebio

4. Dez. 2025, 10:00 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Completes Acquisition Of Vicebio >SAN.FR

24. Okt. 2025, 08:21 UTC

Market Talk
Ergebnisse

Sanofi Results Reflect Improved Efficiency, Should Ease Margin Worries -- Market Talk

24. Okt. 2025, 07:56 UTC

Market Talk
Ergebnisse

Sanofi's Dupixent Drives Growth, But Lantus Gains Set to Fade -- Market Talk

24. Okt. 2025, 05:30 UTC

Ergebnisse

Sanofi 3Q Adj EPS EUR2.91

24. Okt. 2025, 05:30 UTC

Ergebnisse

Sanofi Backs 2025 View

24. Okt. 2025, 05:30 UTC

Ergebnisse

Analysts Saw Sanofi 3Q Business Net Profit at EUR3.29B

Peer-Vergleich

Kursveränderung

Sanofi Prognose

Kursziel

By TipRanks

70.68% Vorteil

12-Monats-Prognose

Durchschnitt 81.09 USD  70.68%

Hoch 117.266 USD

Tief 57 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sanofi – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

2

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

51.665 / 52.38Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat